New hope for Hard-to-Treat colorectal cancer: targeted drug shows promise

NCT ID NCT07213570

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing the drug regorafenib as a second-line treatment for people with advanced colorectal cancer that has a specific mutation in the RAS gene. The study aims to see if a personalized, less intensive treatment approach can help control the cancer and improve quality of life. About 60 participants will receive either regorafenib or standard second-line therapy, and researchers will track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Regorafenib
What this could lead to
If successful, this could offer a less intensive treatment option for people with a specific type of advanced colorectal cancer, potentially improving quality of life while controlling the disease.
What could go wrong
This is a small, early-phase study (phase 2) with only 60 participants, so results may not apply to everyone. The drug can cause side effects like fatigue, hand-foot skin reaction, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istituto Nazionale Tumori | "Fondazione Pascale"

    RECRUITING

    Naples, Italy, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.